INTRODUCTION
============

The non-hematopoietic or stromal cells present in secondary lymphoid organs (SLOs) -- lymph nodes (LNs), spleen, Peyer's patches (PP)- provide the structural and functional underpinnings that allow the most efficient encounter of lymphocytes with their cognate antigens. In this communication, we compare and analyze the contribution of stromal cells in SLOs to a particular type of cellular accumulation, the tertiary lymphoid tissue/organ (TLO).

The immune system generates a repertoire of antigen specific lymphocytes during development of these cells in primary lymphoid organs (the thymus, fetal liver, and bone marrow). Mature lymphocytes regularly transit through SLOs where encounter with cognate antigen is facilitated, leading to an effective immune response. Strategically positioned throughout the body, LNs are encapsulated, highly organized structures; T cells and dendritic cells (DCs) are concentrated in the paracortical region, with B cells and follicular DCs (FDCs) in the cortical region. In the mature LN, resident stromal cells play several critical roles, providing: (1) a meshwork supporting lymphocyte attachment, (2) chemokine signals directing cell subset positioning, (3) a gateway for entrance for lymphocytes (high endothelial venules; HEVs), (4) connections between nodes (lymphatic vessels; LVs), (5) entry points for antigen and antigen presenting cells (APCs; afferent LVs), (6) microvessels, allowing rapid import of small antigens and chemical signals (conduits formed by fibroblastic reticular cells; FRCs), and (7) sites of self-antigen presentation (FRCs, eTACs, LVs).

While SLOs arise during development at key locations in the body, chronic immune activity in the adult can give rise to similar organized accumulations of lymphoid cells in almost any non-lymphoid tissue. These TLOs closely resemble SLOs (particularly LNs) with regard to cellular composition, organization, chemokines, and vasculature. TLOs have been noted during chronic inflammatory processes, including autoimmunity, chronic graft rejection, persistent infection (summarized in [@B18]), atherosclerosis ([@B25]), and cancer ([@B43]; [@B8]). TLOs can also be induced experimentally by tissue-specific expression of certain inflammatory mediators (summarized in [@B18]), including members of the lymphotoxin (LT) family ([@B35]; [@B19]), cytokines crucial for lymphoid organ development and maintenance ([@B55]). Like SLOs, TLOs display organized leukocyte subtype compartmentalization driven by lymphoid chemokines (CCL19, CCL21, and CXCL13), the formation of germinal centers, and a highly organized vascular system, including HEVs, LVs, and perhaps conduits (**Figure [1](#F1){ref-type="fig"}**). Data suggesting that TLOs function as local sites of antigen presentation and lymphocyte activation, including somatic hypermutation and class switching in B cells ([@B56]), suggest that they facilitate local anti-microbial responses, as well as epitope spreading ([@B45]) and autoimmune exacerbation.

![**A comparison of a lymph node with a TLO, a salivary gland from an individual with Sjögren's syndrome.** Note that the HEVs and lymphatic vessels are colored to indicate the existence of mice with green fluorescent HEVs ([@B6]) and red fluorescent lymphatic vessels ([@B59]) that have been developed to facilitate *in vivo* imaging.](fimmu-03-00350-g001){#F1}

Not all inflammatory infiltrates organize into TLOs. Furthermore, in some instance, TLOs can progress from a relatively benign to a destructive phase. In type 1 diabetes in the NOD mouse, initial pancreatic infiltrates are characterized by HEV development and minimal islet destruction, whereas later stages demonstrate frank islet destruction and diabetes ([@B3]). In this model, pancreatic TLOs disappear after removal of the β cell antigen, being replaced by tissue fibroblasts.

In the following sections, we present a detailed comparison of the stromal characteristics of SLOs and TLOs.

LYMPHOID TISSUE ORGANIZER CELLS
===============================

In the early stages of SLO development, various initiating events can activate stromal cells, called lymphoid tissue organizer (LTo) cells (CD4^--^CD3^--^IL7^+^VCAM-1^+^CXCL13^+^LTβR^+^), which recent data suggest may be derived from adipocyte precursors ([@B7]). LTo cells then activate lymphoid tissue inducer (LTi) cells (CD4^+^CD3^--^LTαβ^+^, IL7R^+^ CXCR5^+^) and they in turn, by their cytokine production, activate LTo cells. Although, LTo cells have not yet been isolated from TLOs, LTβR has been shown to induce aortic smooth muscle cells, which are implicated in TLOs in atherosclerosis ([@B25]), to express some genes characteristic of LTos, including CXCL13 and VCAM-1. Both CXCL13 ([@B30]) and VCAM-1 ([@B35]) have been observed in TLOs. However, it is possible that signals from other cells could take over the function of LTos in adult TLOs and LNs. Cells with LTi characteristics have been noted in NOD ([@B20]) and RIPCXCL13 ([@B39]) pancreatic TLOs suggesting that they may play a role in the development of these ectopic tissues.

FOLLICULAR DENDRITIC CELLS
==========================

Follicular DCs form a network supporting B cell follicles in LNs. They are characterized by expression of complement receptors (CR1 and CR2), FcγRIIb, and markers defined by the antibodies FDCM1, FDCM2, and C4. Their roles include capture of antigen--antibody complexes for presentation to B cells and expression of the chemokine, CXCL13, which draws B cells and T follicular helper cells to the follicles via CXCR5.

Follicular DCs (FDCM1^+^CR1^+^) have been noted in TLOs. Their reticular network and association with B cells ([@B19]) in TLOs suggest functional similarities with SLOs. As noted above, CXCL13 is found in TLOs, including those associated with *Helicobacter pylori* ([@B44]), rheumatoid arthritis ([@B40]), Sjögren's syndrome ([@B5]), inflammatory transgenes ([@B35]; [@B30]; [@B19]), and cancer ([@B8]). However, although FDCs are a major source of CXCL13 in LNs, monocytes and macrophages have also been shown to secrete this chemokine in the TLOs associated with rheumatoid arthritis and ulcerative colitis ([@B12]), suggesting additional chemokine sources in chronic inflammation, including LTo cells as noted above. Antigen presentation by FDCs has not been investigated in TLOs.

FIBROBLASTIC RETICULAR CELLS AND CONDUITS
=========================================

The T cell zone of SLOs contains a dense, three-dimensional network of stromal cells called FRCs. This subset of LN stromal cells expresses podoplanin (gp38) but not the lymphatic and blood endothelial cell marker, PECAM (CD31; [@B60]). FRCs produce the extracellular matrix scaffolding that forms a series of very fine microvessels called conduits, detected using an antibody (ER-TR7) that recognizes an undefined antigen ([@B32]). Conduits extend from the subcapsular sinus through the LN cortex, with greatest density in the paracortical T cell zone, and terminate at HEVs. These microchannels are approximately 4--5 nm in diameter and contain a dense network of collagen fibers that collectively limit access to molecules over 70 kDa in size ([@B57]).

In addition to their role in forming conduits, FRCs also participate in the establishment and organization of lymphoid organ microenvironments (reviewed in [@B60]). They are the primary source of the T cell zone-restricted chemokines CCL19 and CCL21, both ligands for CCR7, present on T cells and DCs. These chemokines establish the T zone boundary, facilitate T cell and DC recruitment, and enhance DC maturation and function. FRCs also produce IL-7, critical for naïve T cell survival. The FRC network forms the three-dimensional scaffold along which T cells and DCs migrate; via their shared association with FRCs, interactions between naïve T cells and DCs expressing cognate antigen are facilitated. FRCs express transcripts for some self-antigens and it is has been suggested that they may be involved in self-tolerance ([@B36]). Additional LN stromal cells, termed eTACs, which are gp38^--^ERTR-7^--^, have also been reported to present self-antigens ([@B24]).

Conduits ([@B2]) are believed to serve three key roles in SLOs (reviewed in [@B49]). Given their narrow diameter and positioning, conduits can funnel small lymph-borne antigens from afferent lymphatics to the T cell zone, where FRC-associated resident DCs can receive them. Movement through these microvessels is much more rapid than that which could be achieved by simple filtration through the cell-dense tissue of the LN. Although this reticular network is less dense in the B cell zone, conduits may also serve as a pathway for low molecular weight antigens to reach follicles and facilitate B cell responses ([@B53]). Finally, conduits serve as channels for transmitting small molecule chemical signals, such as chemoattractants from the surrounding tissue, to the paracortical region of the LN, ultimately reaching the endothelial cells lining HEVs.

Fibroblastic reticular cells and conduit-like structures have been noted in several studies of TLOs. [@B39] visualized these stromal elements using two-photon microscopy to detect injected low molecular weight fluorescent dyes, as well as via confocal microscopy and staining with ER-TR7 antibody. In TLOs from NOD or rat insulin promoter (RIP) LTα and RIPCXCL13 transgenic mice FRC-like stromal cells were observed, with the greatest density of staining in the T cell enriched areas of the TLO. In another study of NOD mice, ER-TR7 reactivity was found surrounding pancreatic islets and throughout the acinar tissue, consistent with the expression of this marker on fibroblasts. However, it was also found within the infiltrate ([@B51]), suggesting a supporting stromal network does exist in this case as well. Likewise, using fluorescently labeled ER-TR7 antibodies, we have observed dense staining patterns that resemble conduits in the T cell rich areas of the kidney infiltrates of RIPLTα mice (**Figure [2](#F2){ref-type="fig"}**). However, similar, although less dense, staining could also be seen in kidney samples from control mice, consistent with this as a fibroblast marker. Pulmonary arteries of patients with idiopathic pulmonary arterial hypertension who develop circulating autoantibodies to various vascular self-antigen include TLO-like structures and ER-TR7 antibody positivity ([@B52]). In non-lymphoid human tissues undergoing chronic inflammation (e.g., the liver of patients with primary biliary cirrhosis or the salivary glands of Sjögren's patients), conduit-like gp38^+^CD31^--^LYVE-1^--^ networks similar to those in LNs were seen in most of the T cell dense regions, but not in control tissues.

![**Presumptive conduit in a RIPLTα TLO**. Infiltrate of a RIPLTα mouse with a kidney infiltrate, stained with ER-TR7 (red; **A**) anti-CD3 (green; **B**). Note the presence of the fine network of ER-TR7^+^ cells underlying the infiltrate.](fimmu-03-00350-g002){#F2}

Although cells with the characteristics of FRCs have been observed in TLOs, their functions are unclear. In the absence of a defining capsule and subcapsular sinus it is more difficult to appreciate these structures as conduits transporting low molecular molecules. Whether they can secrete tissue-organizing cytokines, serve as scaffolding for the migration of T and B cells or channel low molecular weigh substances toward TLO compartments remain unanswered questions. Cells phenotypically similar to eTACs have been noted in NOD pancreatic TLOs ([@B24]) raising the question as to whether self-antigen presentation by stromal cells occurs in TLOs and exacerbates or induces tolerance in those locations.

LYMPHATIC VESSELS
=================

Afferent LVs deliver antigen and APCs to LNs and efferent vessels serve as routes for cell traffic to downstream LNs. Recently, an additional LV function was described: expression of self-antigen under the control of AIRE for presentation to T cells ([@B14]). In LNs, DCs accumulate in the subcapsular sinus and transmigrate through the floor of that sinus into the T cell zone, while T cells access the parenchyma of the LN through the peripheral medullary sinuses ([@B10]). Egress from the LN is regulated in part by the high concentration of S~1~P in the lymph and the re-expression of the receptor, S~1~P~1~, on T cells as they leave the node and enter into the efferent lymph ([@B16]).

The presence of vessels with typical lymphatic markers, including LYVE-1 and Prox1, has been documented in the TLOs arising in both clinical settings (autoimmune disease and chronic graft rejection) and experimental models (summarized in [@B34]; [@B18]; [@B23]; [@B37]; [@B25]; [@B48]). Although some macrophages also express LYVE-1, additional characteristics including gp38 expression, thin walls, and absence of red blood cells convincingly demonstrate their identity as LVs.

It has been suggested that TLOs differ from SLOs by the absence of a capsule. Thus, the trafficking patterns analogous to those in LNs ([@B10]), with the DCs percolating and T cells migrating through the peripheral medullary sinus to the parenchyma, might not occur in TLOs. However, TLOs in a variety of chronic kidney diseases ([@B41]) are in contact with a fibrous capsule, suggesting that, similar modes of migration in TLOs may be possible.

During ontogeny, LVs develop after the embryonic blood vessels have formed, sprouting off from the cardinal vein ([@B58]), orchestrated by the homeobox genes (Sox18 and Prox1) and growth factors and their receptors (VEGFC and VEGFR3), and requiring platelets ([@B1]). LTα ([@B48]), DCs and T and B cells have been implicated in the regulation of LVs in inflammation ([@B4]; [@B38]; [@B13]). Regulation of lymphangiogenesis in TLOs is less well understood, although DCs have been implicated in a transgenic model of thyroiditis ([@B50]). LTα regulates LVs in RIPLTαTLOs with less dependence on the LTαβ complex ([@B48]). On the other hand in the CXCL13 induced model of thyroiditis, LVs are inhibited by treatment with a LTβR-Ig ([@B23]).

In some TLOs LVs are packed with lymphocytes ([@B37]) suggesting that they may act to transport activated lymphocytes to downstream LNs, similar to their function in SLOs. Continual administration of FTY720, an S~1~P receptor agonist that prevents egress of lymphocytes from LNs ([@B42]), prevents diabetes in NOD mice ([@B51]). This is only effective if the mice have already developed pancreatic TLOs. Treatment results in additional accumulation of lymphocytes in the pancreatic TLOs, which is reversed upon cessation, resulting in rapid islet destruction and diabetes. These data suggest that lymphocyte trafficking through LVs in TLOs in NOD mice is under regulation of the lymph S~1~P gradient and expression of its receptor by T cells as in a canonical LN. The recent advances in *in vivo* imaging of LNs with the development of mice with red fluorescent LVs ([@B59]) may allow further analysis of the function of LVs in TLOs.

HIGH ENDOTHELIAL VENULES
========================

High endothelial venules, which are post-capillary venules with cuboidal endothelium, are the sites of entry of naïve lymphocytes from the blood stream into LNs. This is accomplished by the interaction of molecules on the surface of lymphocytes with ligands expressed by HEVs. Peripheral node addressin (PNAd), defined by the MECA-79 antibody, is composed of any of a variety of chemically modified core glycoproteins, including GlyCAM-1, CD34, Sgp200, and podocalyxin, to become functional L-selectin ligands ([@B54]). The several enzymes that mediate these post-translational modifications include FucT-IV, FucT-VII, and GlcNAc6ST2 (also called HEC-6ST, LSST, GST-3, HEC-GlcNAc6ST, gene name *Chst4*; [@B29], [@B28]; [@B26],[@B27]; [@B31]), GlcNAc6ST2 is uniquely expressed in high endothelial cells, with the exception of a population of cells in the intestine ([@B37]; [@B33]). Binding to PNAd slows down (tethers) L-selectin^hi^ lymphocytes in their progress through the blood vessels, allowing interaction with chemokines and integrins, eventually facilitating migration of lymphocytes toward chemokines located in the paracortical region (T cells, DCs) or cortex (B cells). PNAd rapidly replaces MAdCAM-1 after birth in mouse peripheral LNs ([@B46]), but is expressed in mucosal LNs together with MAdCAM-1, the ligand for the integrin α~4~β~7~.

High endothelial venules are prominent features of TLOs and their presence can be considered the defining characteristic that distinguishes these organized structures from other forms of inflammatory infiltrate, as they are so crucial for the entrance of naïve cells. HEVs in TLOs (summarized in [@B18]) are characterized by expression of MAdCAM-1, PNAd, and chemokines, particularly CCL21 ([@B30]), as well as the crucial sulfating enzyme GlcNAc6ST2 ([@B9]). HEVs have also been noted in the inflammatory infiltrates associated with atherosclerosis ([@B25]) and several tumors ([@B43]; [@B8]). In fact, the presence of high numbers of these vessels is associated with improved clinical outcomes in breast cancer (longer disease free survival and reduced metastases; [@B43]), suggesting that the HEVs in tumor TLOs could enhance the entrance and priming of naïve lymphocytes into effector cells at the tumor site and lead to improved outcome.

Regulation of HEVs in TLOs appears to be similar to that in SLOs. In LNs, LTα~3~ regulates MAdCAM-1 ([@B15]) and the LTα~1~β~2~ complex regulates PNAd ([@B19], [@B17]; [@B11]) through the alternative NFκB pathway ([@B17]). An LTβ antagonist, LTβR-Ig, inhibits HEVs in LNs ([@B11]; [@B38]; [@B37]) and also in the TLOs that arise in salivary and lacrimal glands of NOD mice ([@B21],[@B22]).

High endothelial venules function in LNs as entry sites for naïve cells. A similar portal function is assumed in TLOs because of the presence of naïve cells at those sites ([@B35]) and evidence of epitope spreading ([@B47]). However, the actual migration of naïve lymphocytes from the blood stream via HEVs into the parenchyma has not yet been visualized in real time in TLOs. Our development of mice with green fluorescent HEVs ([@B6]) and their *in vivo* imaging in LNs ([@B59]) will enable similar analysis in TLOs and resolve whether HEVs function as entry points for naïve cells.

IMPLICATIONS
============

A better understanding of the stromal structure in TLOs could lead the way to therapeutics directed specifically at such structures. Likewise, a clearer appreciation of the inflammatory signals that drive the organization of stromal cells in non-lymphoid tissues into TLO-like structures might allow the design of therapeutic interventions to impede the progression of chronic inflammation, including autoimmune activity. Local interference with the chemokine signals that recruit and organize T and B cells into functional pro-inflammatory structures in non-lymphoid tissues might dampen autoimmune responses and allow for more effective conventional therapy for autoimmune diseases. Since regulatory T cells have been observed in some TLOs, a better understanding of and ability to enhance the tolerance inducing capabilities of APCs might help restrain self-reactivity, limiting exacerbation of autoimmune disease. Treatment with agents that enhance the alternative NF-κB pathway could encourage the development of HEVs in tumors, enhancing the entrance of naïve cells and providing useful new strategies in cancer. Although this concept is actually in contradistinction to treatments currently used to prevent angiogenesis in the tumor setting, understanding the complexity of the stroma in TLOs could provide creative new approaches to disease control.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

This work was supported by NIH R01 DK 057731 (Nancy H. Ruddle), NIH U19-AI082713 (Nancy H. Ruddle), JDRF 4-2007 (Nancy H. Ruddle), U19 AI082713 (Nancy H. Ruddle), NIH R15 AI51674 (Sharon Stranford) and The Mount Holyoke College Faculty Fellowship (Sharon Stranford). We thank Myriam Hill for her contributions to the figures.

[^1]: Edited by: *Mark Christopher Coles, University of York, UK*

[^2]: Reviewed by: *Mark Christopher Coles, University of York, UK; Natalio Garbi, University of Bonn, Germany; Theresa T. Lu, Hospital for Special Surgery/Weill Cornell Medical Center, USA*

[^3]: This article was submitted to Frontiers in Antigen Presenting Cell Biology, a specialty of Frontiers in Immunology.
